The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON IMMUNITYBIO, INC. (IBRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On March 24, 2026, Bloomberg reported that ImmunityBio had receive a Warning Letter from the U.S. Food and Drug Administration (“FDA”) stating that the Company’s Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding the Company’s lead biologic product, Anktiva, including that the drug “can cure and even prevent all cancer.” The FDA thus “determined that the TV ad and podcast are false or misleading” and “make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.”

On this news, ImmunityBio’s stock price fell $1.98, or 21.12%, to close at $7.42 per share on March 24, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased ImmunityBio securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260327191380/en/